Videos
Biomarkers as the Foundation of Tumor-Agnostic Therapy
03/19/2026
At Great Debates Solid Tumors in Miami, Florida, Edward Garon, MD, from the UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California, discusses the evolving role of biomarkers in enabling tumor-agnostic drug approvals across oncology.
Dr Garon highlights the central role of biomarkers in tumor-agnostic approvals, emphasizing how both rare genomic alterations and common markers such as PD-L1, MSI, and tumor mutational burden guide immunotherapy use across cancers.
Source:
Garon E. Plenary: Biomarkers beyond boundaries: Opportunities and challenges of biology crossing histologic categorization. Presented at Great Debates - Solid Tumors; Miami, Florida. March 14-15, 2026.
